Summit Therapeutics PLC (SMMT) stock surged 6.69% in pre-market trading on Monday, fueled by the announcement of a clinical trial collaboration with Pfizer Inc. (PFE) to evaluate its investigational bispecific antibody, ivonescimab, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.
The collaboration aims to accelerate the development of potentially transformative combination therapies by evaluating ivonescimab, a novel PD-1/VEGF bispecific antibody, alongside Pfizer's innovative vedotin ADCs. The goal is to explore the clinical synergy of these therapies and potentially improve the standard of care for patients with serious unmet needs in various solid tumor types.
Under the agreement, Summit will provide ivonescimab for the proposed studies, while Pfizer will be responsible for conducting the operations. The studies, planned to begin in the middle of this year, will be overseen by both companies. Further details on the clinical trials will be announced at a later date.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。